Skip to main content
SpringerLink
Log in

Protein Kinase C Targeting in Antineoplastic Treatment Strategies

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Neoplastic cell survival is governed by a balance between pro-apoptotic and anti-apoptotic signals. Noteworthy among several anti-apoptotic signaling elements is the protein kinase C (PKC) isoenzyme family, which mediates a central cytoprotective effect in the regulation of cell survival. Activation of PKC, and subsequent recruitment of numerous downstream elements such as the mitogen-activated protein kinase (MAPK) cascade, opposes initiation of the apoptotic cell death program by diverse cytotoxic stimuli. The understanding that the lethal actions of numerous antineoplastic agents are, in many instances, antagonized by cytoprotective signaling systems has been an important stimulus for the development of novel antineoplastic strategies. In this regard, inhibition of PKC, which has been shown to initiate apoptosis in a variety of malignant cell types, has recently been the focus of intense interest. Furthermore, there is accumulating evidence that selective targeting of PKC may prove useful in improving the therapeutic efficacy of established antineoplastic agents. Such chemosensitizing strategies can involve either (a) direct inhibition of PKC (e.g., following acute treatment with relatively specific inhibitors such as the synthetic sphingoid base analog safingol, or the novel staurosporine derivatives UCN-01 and CGP-41251) or (b) down-regulation (e.g., following chronic treatment with the non-tumor-promoting PKC activator bryostatin 1). In preclinical model systems, suppression of the cytoprotective function(s) of PKC potentiates the activity of cytotoxic agents (e.g., cytarabine) as well as ionizing radiation, and efforts to translate these findings into the clinical arena in humans are currently underway. Although the PKC-driven cytoprotective signaling systems affected by these treatments have not been definitively characterized, interference with PKC activity has been associated with loss of the mitogen-activated protein kinase (MAPK) response. Accordingly, recent pre-clinical studies have demonstrated that pharmacological disruption of the primary MEK-ERK module can mimic the chemopotentiating and radiopotentiating actions of PKC inhibition and/or down-regulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mellor H, Parker PJ: The extended protein kinase C superfamily. Biochem J 332: 281–292, 1998

    Google Scholar 

  2. Gescher A, Dale IC: Protein kinase C: a novel target in rational drug design. Anticancer Drug Res 4: 93–105, 1989

    Google Scholar 

  3. Weinstein IB: Protein kinase C: implications for cancer prevention and treatment. Mt Sinai J Med 59: 387–393, 1992

    Google Scholar 

  4. Basu A: The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59: 257–280, 1993

    Google Scholar 

  5. Ward NE, Gravitt KR, Fan D: The role of protein kinase C in multidrug resistance. Cancer Treatment Res 73: 41–55, 1994

    Google Scholar 

  6. Philip PA, Harris AL: Potential for protein kinase C inhibitors in cancer therapy. Cancer Treatment Res 78: 3–27, 1995

    Google Scholar 

  7. Grant S, Jarvis WD: Modulation of drug-induced apoptosis by interruption of protein kinase C-dependent signaling pathways: evolution of a new chemotherapeutic strategy. Clin Cancer Res 2: 1915–1920, 1996

    Google Scholar 

  8. Deacon EM, Pongracz J, Griffiths G, Lord JM: Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 50: 124–131, 1997

    Google Scholar 

  9. Spiegel S, Merrill AH: Sphinogolipid metabolism and cell growth regulation. FASEB J 10: 1388–1397, 1996

    Google Scholar 

  10. Kolesnick RN, Kronke M: Regulation of ceramide production and apoptosis. Annu Rev Physiol 60: 643–665,1998

    Google Scholar 

  11. Jarvis WD, Grant S: The role of ceramide in the apoptotic response to antineoplastic agents. Curr Op Oncol 10: 552–559, 1998

    Google Scholar 

  12. Perry DK, Hannun YA: The role of ceramide in cell signaling. Biochim Biophys Acta 1436: 233–243, 1998

    Google Scholar 

  13. Hannun YA, Bell RM: Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science 235: 670–674, 1987

    Google Scholar 

  14. Hannun YA, Bell RM: Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243: 500–507, 1989

    Google Scholar 

  15. Hannun YA, Bell RM: Regulation of protein kinase C by sphingosine and lysosphingolipids. Clin Chem Acta 185: 333–345, 1989

    Google Scholar 

  16. Merrill AH, Nimkar S, Menaldino D, Hannun YA, Loomis SC, Bell RM, Tyagi SR, Lambeth JD, Stevens VL, Hunter R: Structural requirements for long-chain (sphingoid) inhibition of protein kinase C in the cellular effects of these compounds. Biochemistry 28: 3138–3145, 1989

    Google Scholar 

  17. Hannun YA: Sphingolipid messengers as tumor-suppressor lipids. Adv Exp Med Biol 400A: 305–312, 1997

    Google Scholar 

  18. Merrill AH, Nimkar S, Stevens VL, Jamison KK, Liotta DC: Characteristics of the growth-inhibition and cytotoxicity and long-chain (sphingoid) bases: evidence for an involvement of protein kinase C. Biochem Biophys Acta 1051: 37–45, 1990

    Google Scholar 

  19. Sadahira Y, Ruan F, Nakamori S-I, Igarashi Y: Sphingosine-1-phosphate, a specific endogenous signaling molecule controlling tumor cell growth and invasiveness. Proc Natl Acad Sci (USA) 89: 9686–9690, 1992

    Google Scholar 

  20. Merrill AH, Serenit A, Stevens VL, Hannun YA, Bell RM, Kincade JM: Inhibition of phorbol ester-dependent differentiation of human promyelocytic HL-60 cells sphinganine and other long-chain bases. J Biol Chem 261: 12610–12615, 1986

    Google Scholar 

  21. Campbell PI: Toxicity of some charged lipids used in liposome preparations. Cytobios 37: 21–26, 1983

    Google Scholar 

  22. Parenteau H, Ho T-F, Eckel LA, Carroll KK: Effects of a long-chain fatty amine on mammary carcinogenesis. Nutr Cancer 17: 235–241, 1992

    Google Scholar 

  23. Ohta H, Yatomi Y, Sweeney EA, Hakomori S-I, Igarashi Y: A possible role for sphingosine in induction of apoptosis by tumor necrosis factor in human neutrophils. FEBS Lett 355: 267–270, 1994

    Google Scholar 

  24. Ohta H, Sweeney EA, Masamune A, Yatomi Y, Hakomori S-I, Igarashi Y: Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res 55: 691–697, 1995

    Google Scholar 

  25. Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla RK, Bittman R, Grant S: Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem 271: 8275–8284, 1996

    Google Scholar 

  26. Jarvis WD, Fornari FA, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Auer KL, Dent P, Grant S: Coordinate regulation of stress-activated protein kinase and mitogen-activated protein kinase cascades in the apoptotic actions of ceramide and sphingosine in human myeloid leukemia cells. Mol Pharmacol 52: 935–947, 1997

    Google Scholar 

  27. Jones MJ, Murray AW: Evidence that ceramide selectivity inhibits protein kinase C-a translocation. J Biol Chem 270: 5007–5013, 1995

    Google Scholar 

  28. Lee JY, Hannun YA: Ceramide inactivates cellular cPKCa. J Biol Chem 271: 13169–13174, 1996

    Google Scholar 

  29. Abe A, Wu D, Shayman JA, Radin NS: Metabolic effects of short-chain ceramides and sphingolipids on protein kinase C. Eur J Biochem 210: 765–773, 1992

    Google Scholar 

  30. Dobrowsky RT, Hannun YA: Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 267: 5048–5051, 1992

    Google Scholar 

  31. Dovrowsky RT, Kamibayishi C, Mumby MC, Hannun YA: Ceramide activates a heterotrimeric protein phosphatase A2. J Biol Chem 268: 15523–15530, 1993

    Google Scholar 

  32. Hannun YA, Obeid LM, Wolff RA: The novel second messenger ceramide: identification, mechanism of action, and cellular activity. Adv Lipid Res 25: 43–64, 1995

    Google Scholar 

  33. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science 274: 1855–1899, 1996

    Google Scholar 

  34. Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S: Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci (USA) 91: 73–77, 1994

    Google Scholar 

  35. Jarvis WD, Fornari FA, Browning JL, Gewirtz DA, Kolesnick RN, Grant S: Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J Biol Chem 269: 31658–31692, 1994

    Google Scholar 

  36. Porn-Ares MT, Chow SC, Slotte JP, Orrenius S: Induction of apoptosis and potentiation of TNF-and Fas-mediated apoptosis in U937 cells. Exp Cell Res 235: 48–54, 1997

    Google Scholar 

  37. Mayne GL, Murray AW: Evidence that PKC mediates inhibition of TNF-induced apoptosis in U937 histoicytic lymphoma cells. J Biol Chem 273: 24115–24121, 1998

    Google Scholar 

  38. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaels J, Vlodansky F, Fuks Z: PKC mediates basic fibroblastic growth factor protection of endothelial against ionizing radiation. Cancer Res 54: 2591–2597, 1994

    Google Scholar 

  39. Fuks Z, Haimovitz-Friedman A, Kolesnick RN: The role of the sphingomyelin pathway and protein kinase C in radiationinduced cell killing. Important Adv Oncol 5: 19–31, 1995

    Google Scholar 

  40. Kobayashi E, Nakano H, Morimoto M, Tamaoki T: Calphstin C (UCN-1028c), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548553, 1989

    Google Scholar 

  41. Tamaoki T, Takahashi I, Kobayashi E, Nakano H, Akinaga S, Susuki K: Calphostin C (UCN-1029c) and calphostinrelated compounds, a new class of specific and potent inhibitors of protein kinase C. Adv Second Messenger and Phosphoprotein Res 24: 297–401, 1990

    Google Scholar 

  42. Tamaoki T, Nakano H: Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology 8: 732–735, 1990

    Google Scholar 

  43. Tamaoki T: Use and specificity of staurosporine, UCN-01, and calcphostin C as protein kinase inhibitors. Methods Enzymol 201: 340–347, 1994

    Google Scholar 

  44. Herbert JM, Augereau JM, Gleye J, Maffrand JP: Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172: 993–999, 1990

    Google Scholar 

  45. Bertrand R, Solary E, O'Conner P, Kohn KW, Pommier Y: Induction of a common pathway for apoptosis by staurosporine. Exp Cell Res 211: 314–321, 1994

    Google Scholar 

  46. Solary E, Betrand R, Kohn KW, Pommier Y: Differential induction of apoptosis in undifferentiated and differentiated 237 HL-60 cells by DNA topoisomerases I and II inhibitors. Blood 81: 1359–1368, 1993

    Google Scholar 

  47. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemic cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707–1714, 1994

    Google Scholar 

  48. Ikeda K, Kajiwara K, Tanabe E, Takamura S, Kishida E, Masuzawa Y, Kojo S: Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis in HL-60 cells. Biochem Pharmacol 57: 1361–1365, 1999

    Google Scholar 

  49. Byung-Chung S, Se-Young C, Jang-Soo C, Kyong-Tai K: Opposing regulatory effects of PKC on the cAMP cascade in HL60 human promyelocytic leukemia cells. Eur J Pharmacol 353: 105–115, 1998

    Google Scholar 

  50. Thorp KM, Southern L, Matthews N: Effect of serine/ threonine kinase inhibitors on human lymphocytes and U937 cells. Immunology 81: 546–550, 1994

    Google Scholar 

  51. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z: The cell cycle-related difference in susceptibility of HL-60 cells to apoptosis is induced by various antineoplastic agents. Cancer Res 53: 3186–3192, 1994

    Google Scholar 

  52. Rajewski RA, Kosednar DG, Matches TA, Wong OS, Borchett K, Thakker K: Stereospecific analysis of a novel protein kinase C inhibitor. J Pharm Biomed Anal 13: 247–253, 1995

    Google Scholar 

  53. Kedderis LB, Bozigian HP, Kleeman JM, Hall RL, Palmer TE, Harrison SD, Susick RL: Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol 25: 201–207, 1995

    Google Scholar 

  54. Schwartz GK, Juang J, Kelsen D, Albino AP: Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 85: 402–407, 1993

    Google Scholar 

  55. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo F, Kelsen DP, Fuks Z, Albino AP: Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 87: 1394–1399, 1995

    Google Scholar 

  56. Jarvis WD, Fornari FA, Tombes RB, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S: Direct evidence for involvement of mitogen-activated protein kinase (MAPK), rather than stress-activated protein kinase (SAPK), in potentiation of 1-[ß-D-arabinofuranosyl]cytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 54: 844–856, 1998

    Google Scholar 

  57. Grant S: Biochemical modulation of cytosine arabinoside.Pharmac Ther 48: 29–44, 1990

    Google Scholar 

  58. Grant S: 1-[ß-D-arabinofuranosyl]cytosine: molecular and cellular pharmacology. Adv Cancer Res 72: 197–233, 1997

    Google Scholar 

  59. Kucera GL, Capizzi RL: 1-[ß-D-arabinofuranosyl]cytosinediphosphate is formed by reversal of cholinephosphotransferase and not via cytidylyltransferase. Cancer Res 52: 3886–3891, 1992

    Google Scholar 

  60. Strum JL, Small GW, Pauig SB, Daniel LW: 1-[ß-Darabinofuranosyl] cytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem 269: 15493–15497, 1994

    Google Scholar 

  61. Kharbanda SM, Datta R, Kufe DW: Regulation of cjun expression in HL-60 leukemia cells by 1-[ß-Darabinofuranosyl] cytosine; potential involvement of a protein kinase C mechanism. Biochemistry 30: 7747–7752, 1991

    Google Scholar 

  62. Kharbanda SM, Emoto Y, Kiasaki H, Saleem A, Kufe DW: 1-[ß-D-arabinofuranosyl]cytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol diesterresistant myeloid leukemia cells. Mol Pharmacol 46: 67–72, 1994

    Google Scholar 

  63. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S: Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[ß-Darabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47: 838–852, 1994c

    Google Scholar 

  64. Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD: Modulation of 1-[ß-D-arabinofuranosyl]cytosineinduced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncology Res 6: 87–99, 1994

    Google Scholar 

  65. Auzenne E, Leroux E, Hu M, Pollock RE, Feig B, Klostergaard J: Cytotoxicity of sphingolipids as single-or multimodality agents in human melanoma cells. Melanoma Res 8: 227-239, 1998

    Google Scholar 

  66. Klostergaard J, Auzenne E, Leroux E: Characterization of cytotoxicity induced by sphingolipids in multidrug-resistant leukemia cells. Leuk Res 22: 1049–1056, 1998

    Google Scholar 

  67. Fine RL, Chambers TC: P-glycoprotein, multidrug resistance, and protein kinase C. Stemm Cells 14: 47–55m, 1996

    Google Scholar 

  68. Sachs CW, Safa AR, Harrison SD, Fine RL: Partial inhibition of multidrug-resistance by safingol os independent of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270: 26639–26648, 1995

    Google Scholar 

  69. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita T: Staurosporine, a potent inhibitor of phospholipid/calcium-dependent kinases. Biochim Biophys Res Commun 135: 397–402, 1986

    Google Scholar 

  70. Ruegg UT, Burgess GM: Staurosporine, K-252, and UCN-01: potent and non-specific inhibitors of protein kinases. Trends Pharmacol Sci 10: 218–220, 1989

    Google Scholar 

  71. Plumas J, Jacob MC, Chaperot L, Moleus JP, Sotta JJ, Benson JC: Tumor B-cells from non-Hodgkins lymphoma are resistant to CD95 (Fas/APO1)-mediated apoptosis. Blood 91: 2875–2885, 1998

    Google Scholar 

  72. Qiao L, Koustos M, Tsai LL, Kozoni V, Guzman J, Shiff SJ, Rigas B: Staurosporine inhibits proliferation, alters cell cycle distribution, and induced apoptosis in HT-29 human colon adenocarcinoma cells. Cancer Lett 107: 83–89, 1996

    Google Scholar 

  73. Shirohawa T, Sakakura C, Sewwney EA, Ozawa M, Takemoto M, Nishizawa K, Ohi Y, Igarashi Y: Sphingosine induces apoptosis in androgen-dependent human prostatic carcinoma DU-145 cells. FEBS Lett 407: 87–100, 1997

    Google Scholar 

  74. Abiko Y, Arai J, Mitamura J, Kaku T: Alteration of protooncogenes during apoptosis in the squamous cell carcinoma cell line SAS induced by staurosporine. Cancer Lett 118: 101–107, 1997

    Google Scholar 

  75. Boix J, Liecke N, Guste VJ, Comella JX: Characterization of the cell death process induced by staurosporine in human neuroblastoma cells. Neuropharmacol 36: 811–821, 1997

    Google Scholar 

  76. Janss AJ, Levow C, Bernhard EJ, Muschel RJ, McKenna WG, Sutton L, Phillips PC: Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines. Exp Cell Res 243: 29–38, 1998

    Google Scholar 

  77. Couldwell WT, Hinton DR, Hu S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43–46, 1994

    Google Scholar 

  78. Kobayashi D, Watanabe N, Yamauchi N, Tsei N, Sato T, Sasaki H, Okamoto T, Nitsu Y: Protein kinase C inhibitors 238 augment TNF-induced apoptosis in normal human diploid cells. Chemotherapy 43: 415–423, 1997

    Google Scholar 

  79. Bertrand R, Solary E, O'Conner P, Kohn KW, Pommier Y: Induction of a common pathway for apoptosis by staurosporine. Exp Cell Res 211: 314–321, 1994

    Google Scholar 

  80. Lock RB, Thompson BS, Sullivan DM, Stribinskiene L: Potentiation of etoposide-induced apoptosis by human tumor cells is associated with events downstream of DNAdrug complex formation. Cancer Chemother Pharmacol 39: 399–409, 1997

    Google Scholar 

  81. Takahashi I, Kobayashi E, Asano K, Yoshida M: UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot 40: 1782–1784, 1987

    Google Scholar 

  82. Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M: UCN-01 and UCN-02, new selective inhibitors of protein kinase C. Purification, physico-chemical properties, structural determination and biologic activities. J Antibiot 42: 571–576, 1989

    Google Scholar 

  83. Tamaoki T, Nakano H: Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology 8: 732–735, 1990

    Google Scholar 

  84. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51: 4888–4892, 1991

    Google Scholar 

  85. Shimizu E, Zhao MR, Nakanishi H, Yamamoto A, Yoshida S, Takada M, Ogura T, Sone S: Differing effects of staurosporine and UCN-01 on Rb phosphorylation and expression of lung cancer cell lines. Oncology 53: 494–504, 1996

    Google Scholar 

  86. Shao R-G, Cao C-X, Pommier Y: Activation of PKCα downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells. J Biol Chem 50: 31321–31325, 1997

    Google Scholar 

  87. Wang Q, Worland PJ, Clark JL, Carlson BA, Sauseville EA: Apoptosis in 7-hydroxystaurosporine-treated T-lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6: 927–936, 1995

    Google Scholar 

  88. Akinaga S, Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21-Cip1/Waf1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57: 1495–1501, 1997

    Google Scholar 

  89. Bunch RT, Eastman A: 7-hydrostaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese Hamster Ovary cells. Cell Growth Differ 8: 779–788, 1997

    Google Scholar 

  90. Akinaga S, Nomura K, Gomi K, Okabe M: Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32: 183–189, 1993

    Google Scholar 

  91. Bunch RT, Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2: 791–797, 1996

    Google Scholar 

  92. Shao R-G, Cao C-X, Shimizu T, O'Connor PM, Kohn KW, Pommier Y: Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53. Cancer Res 57: 4029–4035, 1997

    Google Scholar 

  93. Wang S, Vrana JA, Bartimole T, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S: Agents that downregulate or inhibit kinase C circumvent resistance to 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in human leukemia cells overexpressing Bcl-2.Mol Pharmacol 52: 1000–1009, 1997

    Google Scholar 

  94. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM: UCN-01: a potent abrogator of G2 checkpoint functionin cancer cells with disrupted p53. J Natl Cancer Inst 88: 956–965, 1996

    Google Scholar 

  95. Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Sivestrini R, Watanabe N, Piwnica-Worms H, O'Connor PM: UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivated of the Wee1Hu kinase and activation of Cdc25C phosphatase. J Biol Chem 273: 38455–44464, 1998

    Google Scholar 

  96. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sauseville EA, Akinaga S, Kuwabara T, Kobayashi S: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α 1-acid glycoprotein. Cancer Res 58: 3248–3255, 1998

    Google Scholar 

  97. Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, Kuwabara T, Kobayashi S, Sugiyama Y: Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α 1-acid glycoprotein in humans. Cancer Res 59: 1054–1060, 1999

    Google Scholar 

  98. Meyer T, Regenass U, Fabbro D, Altari E, Rosal J, Muller M, Caravatti G, Matter A: A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Eur J Cancer 43: 851–856, 1989

    Google Scholar 

  99. Ikegami Y, Yano S, Nakao K: Antitumor effect of CGP-41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol 70: 65–72, 1996

    Google Scholar 

  100. Harkin ST, Cohen GM, Gescher A: Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Mol Pharmacol 54: 663–670, 1998

    Google Scholar 

  101. Gescher A: Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 31: 721–728, 1998

    Google Scholar 

  102. Zhang W, Dziak RM, Aletta JM: EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteblastic cells. J Cell Physiol 162: 348–358, 1995

    Google Scholar 

  103. Spinedi A, Oliverio S, DiSano F, Piacentini M: Calpain involvement in calphostin-induced apoptosis. Biochem Pharmacol 56: 1489–1592, 1998

    Google Scholar 

  104. Zhu DM, Narla RK, Fang WH, Chia NC, Uckun FM: Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin Cancer Res 4: 2967–2976, 1998

    Google Scholar 

  105. Leszczynski D: Regulation of cell cycle and apoptosis by protein kinase C in rat myeloid leukemia cells. Oncol Res 7: 471–479, 1995

    Google Scholar 

  106. Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J: Apoptosis of human glioma cells in response to calphostin C, a specific inhibitor of protein kinase C. J Neurosurg 83: 1008–1016, 1995

    Google Scholar 

  107. Weinstein IB, Begemann M, Zhou P, Han EK, Sgambuto A, Doki Y, Arber N, Ciapparone M, Yamamoto H: Disorders in cell circuitry associated with multistage carcinogenesis: explotable targets for cancer prevention and chemotherapy. Clin Cancer Res 3: 2696–2702, 1997

    Google Scholar 

  108. Begemann M, Kashimawo SA, Lunn RM, Delohery T, Choi J, Kine S, Heitjani DF, Santella RM, Schiff PB, Bruce NJ, Weinstein IB: Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated 239 with apoptosis and inhibition of CDC2 kinase. Anticancer Res 18: 3139–3152, 1998

    Google Scholar 

  109. Minara MD, Felipo V, Grisola S: Differential effects of the protein kinase C inhibitors H7 and calphostin C on the cell cycle. Brain Res 596: 157–162, 1992

    Google Scholar 

  110. Pollack IF, Kawecki S: The effect of calphostin C, a potent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J Neurooncol 31: 255–266, 1997

    Google Scholar 

  111. Ozaki I, Tani E, Ikemoto H, Kitegawa H, Fujikawa H: Activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase and p38 kinase in calphostin C-induced apoptosis requires caspase-3-like proteases but is dispensable for cell death. J Biol Chem 274: 5310–5317, 1999

    Google Scholar 

  112. Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Shrivastav M, Chung T, Stadler WM, Rinker-Schaeffer CW: Activated calphostin C cytotoxicty is independent of p53 status and in vivo metastatic potential. Clin Cancer Res 4: 2391–2398, 1998

    Google Scholar 

  113. Diwa Z, Lown JW: Photosensitization with anticancer agents: EPR studies of photodynamic activation of calphostin C. Free Radical Biol Med 16: 645–652, 1994

    Google Scholar 

  114. Murata M, Nagai M, Fijita M, Ohmori M, Takehara J: Calphostin C synergistically induces apoptosis with VP-16 in lymphoma cells which express abundant phosphorylated BCL2. Cell Mol Life Sci 53: 737–743, 1997

    Google Scholar 

  115. Weller M, Trepel M, Grimmel C, Schabet M, Brememn D, Krajewski S, Reed JC: Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of BCL2 expression, and does not require wild type p53. Neurol Res 19: 459–470, 1997

    Google Scholar 

  116. Gupta S, Patel K, Singh H, Gollapudi S: Effect of calphostin C on daunorubicin resistance in P388/ADR cells and HL-60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 76: 139–145, 1994

    Google Scholar 

  117. Findik D, Song Q, Hidaka H, LAVIN M: Protein kinase A inhibitors enhance radiation-induced apoptosis. J Cell Biochem 57: 12–21, 1995

    Google Scholar 

  118. Pettit GR, Herald CL, Boubek DL, Herald DL, Arnold E, Clardy J: Isolation and structure of bryostatin 1. J Am Chem Soc 104: 6846–6948, 1982

    Google Scholar 

  119. Hess AD, Silankis MK, Esa AH, Pettit GR, May WS: Activation of human T lymphocytes by bryostatin 1. J Immunol 141: 3263–3269, 1988

    Google Scholar 

  120. Kennedy MJ, Prestigiacomo LJ, Tylor G, May WS, Davidson NE: Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 52: 1278–1283, 1992

    Google Scholar 

  121. Dale IL, Gescher A: Effects of activators of protein kinase C, including bryostatin 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43: 158–163, 1989

    Google Scholar 

  122. Schucter LM, Esa AH, May WS, Laulis MK, Pettit GR, Hess AD: Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51: 682–687, 1991

    Google Scholar 

  123. Berkow RL, Kraft AS: Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Biochem Biophys Res Commun 131: 1109–1116, 1985

    Google Scholar 

  124. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores RA, Yuspa SH: Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol ester in SENCAR mouse skin. Carcinogenesis 8: 1343–1346, 1987

    Google Scholar 

  125. Kraft AS, Smith JB, Berkow RL: Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci (USA) 83: 1334–1338, 1986

    Google Scholar 

  126. Rodriguez-Pena R, Rozengurt E: Disappearance of Ca2+-sensitive, phospholipid-dependent kinase activity in phorbol ester-treated 3T3 cells. Biochem Biophys Res Commun 120: 1053–1059, 1984

    Google Scholar 

  127. Szallasi Z, Smith CB, Pettit GR, Blumberg PM: Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts.J Biol Chem 269: 2118–2124, 1994

    Google Scholar 

  128. Hocevar BA, Fields AP: Selective translocation of β II-protein kinase C to the nucleus of human promyelocytic leukemia (HL-60) cells. J Biol Chem 266: 28–33, 1991

    Google Scholar 

  129. Isakov N, Galron D, Mustelin T, Pettit GR, Altman A: Inhibition of phorbol ester-induced T cell proliferation by bryostatin 1 is associated with rapid degradation of protein kinase C. J Immunol 150: 1195–1204, 1993

    Google Scholar 

  130. Lee H-W, Smith L, Pettit GR, Vinitsky A, Smith JB: Ubiquitinization of protein kinase C-_ and degradation by the proteosome. J Biol Chem 271: 20973–20976, 1996

    Google Scholar 

  131. May WS, Sharkis SS, Esa AH, Gebbia V, Kraft AS, Pettit GR, Sensenbrenner LL: Antineoplastic bryostatins are multipotent stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci (USA) 84: 8483–8487, 1987

    Google Scholar 

  132. Jones R, Sharkis S, Miller C, Rowinsky E, Burke P, May WS: Bryostatin 1, a unique biologic response modifier: antileukemic activity in vitro. Blood 75: 1319–1323, 1990

    Google Scholar 

  133. Kraft AS, William F, Pettit GR, Lilly MB: Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 49: 1287–1293, 1989

    Google Scholar 

  134. Grant S, Traylor R, Bhalla K, McCrady C, Pettit GR: Effect of a combined exposure to ara-C, bryostatin 1, and rGM-CSF on the in vitro clonogenic growth of normal and leukemic human hematopoietic progenitor cells. Leukemia 5: 432–439, 1992

    Google Scholar 

  135. Hu Z-B, Gignac SM, Uphoff CC, Quentmeier H, Steube KG, Drexler HG: Induction of differentiation of B-cell leukemia cell lines JVM-2 and EHEB by bryostatin 1. Leuk Lymphoma 10: 135–142, 1993

    Google Scholar 

  136. Maki A, Diwakaran H, Redman B, Al-Asfar S, Pettit GR, Mohammad RM, Al-Katib A: The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-cancer Drugs 6: 392–397, 1995

    Google Scholar 

  137. Al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL: Bryostatin 1 modulation of the acute lymphoblastic leukemia cell line Reh. J Immunother 14: 33–42, 1993

    Google Scholar 

  138. Al-Katib A, Mohammad RM, Dan M, Hussein ME, Akhtar A: Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol 21: 61–65, 1993

    Google Scholar 

  139. Hornung RL, Pearson JW, Beckwith M, Longo DL: Preclinical evaluation of bryostatin 1 as an anti-cancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52: 101–107, 1992

    Google Scholar 

  140. Jarvis WD, Gewirtz D, Povirk L, Turner A, Traylor R, Pettit GR, Grant S: Effect of bryostatin 1 and other activators of protein kinase C on 1-β-D-arabinofuranosylcytosineinduced apoptosis in HL-60 human promyelocytic leukemia cells. Biochemical Pharmacology 47: 839–852, 1994

    Google Scholar 

  141. Wang S, Vrana JA, Bartimole T, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S: Agents that down240 regulate or inhibit protein kinase C circumvent resistance to 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in human leukemia cells overexpressing Bcl-2.Mol Pharmacol 52: 1000–1009, 1997

    Google Scholar 

  142. Wang S, Guo Y, Castillo T, Dent P, Grant S: Potentiation of taxol-induced apoptosis and anti-proliferative effects in human myeloid leukemia cells (U937) by bryostatin 1. Biochem Pharmacol 56: 635–644, 1998

    Google Scholar 

  143. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL: Successful treatment of Waldenstrom's macroglobulinemia with combination of biological and chemotherapy agents. Cancer Res 54: 165–168, 1994

    Google Scholar 

  144. Mohammad RM, Diwarkaran H, Maki A, Emara MA, Pettit GR, Redman B, Al-Katib A: Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19: 668–673, 1995

    Google Scholar 

  145. Mohammad RM, Katato K, Almatchy VP, Wall N, Liu K, Schultz CP, Mantsch HH, Varterasian M, Al-Katib AM: Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by chlorodeoxyadenosine: preclinical studies. Clin Cancer Res 4: 445–453, 1998

    Google Scholar 

  146. Bear HD, McFadden A, Turner A, Grant S: Bryostatin 1 induces long-term depletion of protein kinase C in vivo following a single intravenous administration. Anti-Cancer Drugs 6: 384–391, 1995

    Google Scholar 

  147. Haldar S, Chintapalli J, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229–233, 1996

    Google Scholar 

  148. Jarvis WD, Fornari FA, Tombes RM, Martin HA, Erkulla RK, Bittman R, Schwartz GK, Dent P, Grant S: Evidence for involvement of MAPK, rather than SAPK, in potentiation of 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis by interruption of the PKC pathway. Mol Pharmacol 54: 844–856, 1998

    Google Scholar 

  149. Philip P, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL: Phase I study of bryostatin 1: assessment of interleukin-6 and tumour necrosis factor-α in vivo. J Natl Cancer Inst 85: 1812–1818, 1993

    Google Scholar 

  150. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Stern P, McDermott R, Potter M, Pettit GR: A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418–424, 1993

    Google Scholar 

  151. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, Pettit GR: A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 72: 461–468, 1995

    Google Scholar 

  152. Scheid C, Prendiville J, Jayson G, Crowther DB, Fox B, Pettit GR, Stern PL: Immunomodulation in patients receiving bryostatin 1 in a phase I clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Chemother Immunother 39: 223–230, 1994

    Google Scholar 

  153. Grant S, Roberts J, Bear HD, Poplin E, Tombes M, Kyle B: Phase Ib pharmacodynamic trial of bryostatin 1 in patients with advanced malignancies. Clin Cancer Res 4: 611–618, 1998

    Google Scholar 

  154. Vartersian ML, Mohammad RM, Eilander DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BDM, Al-Katib A: Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16: 56–62, 1998

    Google Scholar 

  155. Carr ME, Carr SL, Grant S: A sensitive platelet activationbased functional assay for the anti-leukemic agent bryostatin 1. Anti-Cancer Drugs 6: 1–8, 1995

    Google Scholar 

  156. Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS: Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 56: 802–808, 1996

    Google Scholar 

  157. Xia Z, Dickens M, Raingeaud J, David RJ, Greenberg ME: Opposing effects of ERK, JNK, and RK kinases on apoptosis. Science 270: 1326–1331, 1995

    Google Scholar 

  158. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S: The roles of signaling by the p42-ERK1/p44-ERK2 mitogen-activated protein kinase (MAPK) pathway: a potential route to radiosensitization and chemosensitization in leukemic cells. Leukemia 12: 1843–1850, 1998

    Google Scholar 

  159. Brach MA, Kharbanda SM, Herrmann F, Kufe DW: Activation of the transcription factor K B in human myeloid leukemia cells treated with 1-[β-D-arabinofuranosyl]cytosine.Mol Pharmacol 41: 60–63, 1992

    Google Scholar 

  160. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD-098059 is a specific inhibitor of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489–27494, 1995

    Google Scholar 

  161. Dudley DT, Pang I, Decker SJ, Brifges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci (USA) 92: 7686–7689, 1995

    Google Scholar 

  162. Wang S, Wang Z, Boise L, Dent P, Grant S: Loss of the BCL-2 phosphorylation loop increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem Biophys Res Commun 259: 67–72, 1999

    Google Scholar 

  163. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitti WJ, Earl RA, Hobbs F, Copeland RA, Nagolda RL, Soliere PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623–18632, 1998

    Google Scholar 

  164. Wang CY, Cusack JC, Liu R, Baldwin AS: Control of indicible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF K B. Nat Med 5: 412–417, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Medical College of Virginia, Richmond, VA, USA

    W. David Jarvis & Steven Grant

Authors
  1. W. David Jarvis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jarvis, W.D., Grant, S. Protein Kinase C Targeting in Antineoplastic Treatment Strategies. Invest New Drugs 17, 227–240 (1999). https://doi.org/10.1023/A:1006328303451

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006328303451

Search

Navigation